A BeNeLux ISPE event on 23 September 2025 put 'business continuity' and 'culture' next to 'compliance' in the same talk title. That framing is the story: cleaning validation is being repositioned as an operational capability that keeps multi-product campaigns running, not a documentation obligation discharged before an inspection.
What happened
On 23 September 2025 the ISPE BeNeLux Commissioning, Qualification & Validation (C&Q&V) Community of Practice, together with the ISPE Emerging Leaders group, held a half-day Cleaning Validation event at MSD Boxmeer in the Netherlands. The room held 45; 44 registered at EUR 40 for non-members, and MSD Animal Health hosted and sponsored the afternoon. The programme ran from a 12:45 site tour, through a 14:30 welcome, to four speaker sessions between 15:00 and 17:30, a Q&A and networking.
The line-up is the signal. Paul Tiemeijer (Managing Consultant at Progress, over thirty years in pharma and fifteen in cleaning validation) framed the topic as "Leadership in Cleaning Validation: a delicate balance between compliance, business continuity, culture and the future." Ilke Diels and Wout van Beylen presented a comprehensive approach to cleaning validation in theory and practice; Hidde Osinga took on the challenges of multi-drug production companies; Ngan Nguyen closed on the route from QC analyst to cleaning validation expert. ISPE listed the themes as emerging trends in cleaning validation, risk-based approaches navigating the space between compliance and business drivers, and advances in automation and data-driven validation.
What the event signals
"Business continuity" and "culture" now sit in the same sentence as "compliance" — deliberately. That is a repositioning. Where cleaning validation was long sold as a documentation obligation to be discharged before an inspection, this framing treats it as an operational capability that keeps campaigns running, protects yield and preserves supply. A cleaning failure at a multi-product site is not only a deviation: it is lost batches, delayed campaigns, repeated cleaning and requalification, and inventory that cannot be released.
Why it matters
PDA Technical Report No. 29 already argued that risk analysis in cleaning validation must include business risk, not only patient risk — including steps taken to minimise lost product from contamination even where release controls already exist. Multi-drug manufacturing sharpens that point. Shared equipment means the cleaning programme mediates every product transition: worst-case and matrixing decisions determine how much validation capacity a portfolio consumes and how quickly a new product can be introduced. Culture is the other variable — the most defensible acceptance criteria fail where operators, engineers and QC do not own the cleaning step. And the future direction ISPE named, automation and data-driven validation, is what turns a validated state into a genuinely monitored one.
Questions for our programme
- Can we articulate the business-continuity value of our cleaning programme in terms a site leadership team will fund — changeover time, campaign length, batch loss — not only inspection readiness?
- When we introduce a new product into a shared train, does our matrixing and worst-case logic genuinely govern the decision, or is it retrofitted once commercial pressure arrives?
- Which part of our cleaning culture is weakest: operator ownership of manual cleaning, engineering control of CIP parameters, or QC ownership of the analytical methods?
- Is our ongoing monitoring automated enough to detect process drift before it becomes a deviation?
Wider context
The lifecycle framing is settled elsewhere. The ISPE Guide: Cleaning Validation Lifecycle — Applications, Methods, and Controls (2020, reviewed by regulators) sets out design, qualification and ongoing monitoring; Health Canada's GUI-0028 and PIC/S PI 006-3 describe the same three phases; EU GMP Annex 1 embeds equipment cleaning within a broader contamination control strategy. What the BeNeLux event adds is the operational and human layer — leadership, culture and continuity. A recent PDA Journal comparison of matrix versus product-specific approaches reaches a comparable practical conclusion, favouring a combined strategy that balances regulatory compliance against operational performance.
Sources
- ISPE, "Cleaning Validation" — ISPE BeNeLux C&Q&V CoP event, 23 September 2025, MSD Boxmeer (event page and agenda). Primary source; association-published.
- PDA Technical Report No. 29 (Revised 2012), Points to Consider for Cleaning Validation — PDA, industry association, peer-reviewed task force report.
- PDA Letter, "Lifecycle Approach Wipes Away Cleaning Validation Concerns" — PDA published case study, multiproduct injectables manufacturer.
- ISPE Guide: Cleaning Validation Lifecycle — Applications, Methods, and Controls (2020) — ISPE guidance document, regulator-reviewed.
- Health Canada, Cleaning validation guide GUI-0028 — regulator guidance, lifecycle approach.
- PDA Journal of Pharmaceutical Science and Technology, "Comparative Study of Matrix vs. Product-Specific Cleaning Validation Approaches" — peer-reviewed, early access.
Validation takeaway
Cleaning validation is being repositioned from an inspection-facing documentation exercise to an operational capability. The practical consequence for a validation programme is that the cleaning validation master plan should be able to state, in business terms, what the cleaning programme protects — changeover time, campaign continuity, batch yield — alongside its HBEL-based acceptance criteria. Where matrixing and worst-case logic decide which products may share a train, those decisions are the operational lever, and the lifecycle stages of design, qualification and ongoing monitoring are the mechanism that keeps them defensible.
Questions worth asking in our own programme
- Can we articulate the business-continuity value of our cleaning programme in terms a site leadership team will fund — changeover time, campaign length, batch loss — not only inspection readiness?
- When we introduce a new product into a shared train, does our matrixing and worst-case logic genuinely govern the decision, or is it retrofitted once commercial pressure arrives?
- Which part of our cleaning culture is weakest: operator ownership of manual cleaning, engineering control of CIP parameters, or QC ownership of the analytical methods?
- Is our ongoing monitoring automated enough to detect process drift before it becomes a deviation?
